LU92005I2 - golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®) - Google Patents

golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)

Info

Publication number
LU92005I2
LU92005I2 LU92005C LU92005C LU92005I2 LU 92005 I2 LU92005 I2 LU 92005I2 LU 92005 C LU92005 C LU 92005C LU 92005 C LU92005 C LU 92005C LU 92005 I2 LU92005 I2 LU 92005I2
Authority
LU
Luxembourg
Prior art keywords
simponi
golimumab
pharmaceutically acceptable
acceptable derivatives
tnf
Prior art date
Application number
LU92005C
Other languages
English (en)
Original Assignee
Mathilda And Terrence Kennedy Inst Of Rheumatology Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24773909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mathilda And Terrence Kennedy Inst Of Rheumatology Trust filed Critical Mathilda And Terrence Kennedy Inst Of Rheumatology Trust
Publication of LU92005I2 publication Critical patent/LU92005I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
LU92005C 1996-08-01 2012-05-23 golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®) LU92005I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/690,775 US6270766B1 (en) 1992-10-08 1996-08-01 Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP97933799A EP0914157B1 (fr) 1996-08-01 1997-08-01 Anticorps anti facteur de necrose tumorale / recepteur de tnf et methotrexate dans le traitement des maladies auto-immunes

Publications (1)

Publication Number Publication Date
LU92005I2 true LU92005I2 (fr) 2012-07-23

Family

ID=24773909

Family Applications (4)

Application Number Title Priority Date Filing Date
LU92005C LU92005I2 (fr) 1996-08-01 2012-05-23 golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)
LU92004C LU92004I2 (fr) 1996-08-01 2012-05-23 adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
LU92098C LU92098I2 (fr) 1996-08-01 2012-11-16 Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
LU92099C LU92099I2 (fr) 1996-08-01 2012-11-16 Golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)

Family Applications After (3)

Application Number Title Priority Date Filing Date
LU92004C LU92004I2 (fr) 1996-08-01 2012-05-23 adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
LU92098C LU92098I2 (fr) 1996-08-01 2012-11-16 Adalimumab et ses dérivés pharmaceutiquement acceptables (HUMIRA®)
LU92099C LU92099I2 (fr) 1996-08-01 2012-11-16 Golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)

Country Status (11)

Country Link
US (10) US6270766B1 (fr)
EP (3) EP1941904B1 (fr)
AT (2) ATE305798T1 (fr)
AU (1) AU719015B2 (fr)
CA (2) CA2791778A1 (fr)
DE (1) DE69734317T2 (fr)
DK (3) DK0914157T3 (fr)
ES (3) ES2378446T3 (fr)
LU (4) LU92005I2 (fr)
PT (2) PT1593393E (fr)
WO (1) WO1998005357A1 (fr)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
DE69027121T3 (de) * 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) * 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP0980258A1 (fr) * 1997-05-12 2000-02-23 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
HUP0103563A3 (en) * 1998-08-31 2004-04-28 Biogen Idec Ma Inc Cambridge Method of modulating memory effector t-cells and compositions
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
WO2001008696A2 (fr) * 1999-07-28 2001-02-08 Schering Corporation Utilisation combinee d'interleukine 10 et de methotrexate pour therapie immunomodulatrice
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
US8147824B2 (en) * 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
CN100494182C (zh) * 2000-05-12 2009-06-03 基酶有限公司 肿瘤坏死α因子信号的调节因子
US20110195063A1 (en) * 2000-08-07 2011-08-11 Centocor, Inc. Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
EP1372720A4 (fr) * 2001-03-02 2006-07-26 Medimmune Inc Prevention ou traitement de troubles inflammatoires ou auto-immuns par l'administration d'antagonistes de l'integrine alpha v beta 3
EP1379275A4 (fr) * 2001-03-14 2005-12-21 Centocor Inc Proteines provenant de l'immunoglobuline associees a la bronchopneumopathie chronique obstructive, compositions, procedes et utilisations
CA2445826C (fr) 2001-05-02 2014-03-25 Purdue Research Foundation Traitement et diagnostic de maladies associees aux macrophages
CA2817619A1 (fr) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
CA2454618C (fr) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methodes de traitement ou de prevention de troubles sclereux par l'usage d'agents se liant a cd2
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ATE493980T1 (de) * 2002-11-21 2011-01-15 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US20050042219A1 (en) * 2002-12-05 2005-02-24 Woulfe Susan L. Engineered Fab' fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
EP1460088A1 (fr) * 2003-03-21 2004-09-22 Biotest AG Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE602004017452D1 (de) 2003-05-30 2008-12-11 Purdue Research Foundation Diagnoseverfahren für atherosklerose
AR044927A1 (es) * 2003-06-25 2005-10-12 Elan Pharm Inc Metodos y composiciones para tratar la artritis reumatoidea
US20060210563A1 (en) * 2003-07-25 2006-09-21 Juan Lopez De Silanes Administration of anti-cytokine f(ab')2 antibody fragments
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP1747291A2 (fr) * 2004-05-04 2007-01-31 Genaissance Pharmaceuticals, Inc. Marqueurs haplotypes et procedes d'utilisation de ceux-ci pour determiner la reponse a un traitement
CA2565259A1 (fr) * 2004-05-07 2005-12-08 Astellas Us Llc Polypeptide lfa-3 soluble destine a traiter de troubles viraux
US20060083741A1 (en) * 2004-10-08 2006-04-20 Hoffman Rebecca S Treatment of respiratory syncytial virus (RSV) infection
WO2006058024A2 (fr) * 2004-11-22 2006-06-01 Smith Henry J Recepteurs cellulaires utilises comme excipients pour composes pharmaceutiques servant dans le traitement de l'arthrite, et des troubles inflammatoires et immunitaires
RU2007128036A (ru) * 2004-12-23 2009-01-27 Пердью Рисерч Фаундейшн (Us) Способ получения изображения позитронно-эмиссионной томографией
EP2529619B1 (fr) 2005-02-17 2015-09-23 Biogen MA Inc. Traitement des troubles neurologiques
JP5339901B2 (ja) * 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
AU2016203976B2 (en) * 2005-11-09 2018-02-01 Abt Holding Company Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
EP2007426A4 (fr) 2006-04-10 2010-06-16 Abbott Biotech Ltd Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
US20080064626A1 (en) * 2006-09-08 2008-03-13 Zanella John M Methods of treating tendonitis in a subject by using an anti-cytokine agent
KR20090078349A (ko) 2006-10-12 2009-07-17 제넨테크, 인크. 림포톡신-알파에 대한 항체
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
US8586595B2 (en) * 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
CA2688308A1 (fr) * 2007-05-25 2008-12-04 Purdue Research Foundation Methode d'imagerie d'infections localisees
JP5719591B2 (ja) 2007-06-08 2015-05-20 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 抗ｔｎｆ応答性または非応答性を予測するためのバイオマーカー
EP2171451A4 (fr) 2007-06-11 2011-12-07 Abbott Biotech Ltd Procédés de traitement de l'arthrite idiopathique juvénile
WO2009090189A1 (fr) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Composition de protéine pulvérisée et procédés de fabrication de celle-ci
ES2610327T3 (es) * 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
BRPI0909048A2 (pt) * 2008-03-13 2015-11-24 Biotest Ag composição farmacêutica, e, método de tratamento de uma doença autoimune
HUE028962T2 (en) * 2008-03-13 2017-01-30 Biotest Ag Active ingredient for treating disease
KR20110061630A (ko) * 2008-09-29 2011-06-09 바이오테스트 아게 질병 치료용 조성물
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
EP2718328A4 (fr) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions et procédés pour augmenter la demi-vie sérique
CA2853833A1 (fr) 2011-11-08 2013-05-16 Arena Pharmaceuticals, Inc. Modulateurs pour le recepteur mas couple a la proteine g et traitement des troubles qui y sont apparentes
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
RU2677658C2 (ru) * 2012-07-05 2019-01-18 Тайвэн Липосом Ко, Лтд. Способы лечения артрита
US8958362B2 (en) * 2012-08-24 2015-02-17 William Marsh Rice University Method and system for wirelessly transmitting data
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
KR101759687B1 (ko) 2013-01-25 2017-07-19 타이몬, 엘엘씨 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014182673A1 (fr) 2013-05-07 2014-11-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur mas couplé à la protéine g et traitement de troubles apparentés
US9827181B2 (en) 2013-06-05 2017-11-28 Industrial Technology Research Institute Method and pharmaceutical composition for hair growth
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10298750B2 (en) * 2013-11-21 2019-05-21 Vodafone Ip Licensing Limited Telecommunication networks for content delivery and lawful interception, content filtering and further content services using a SAVI platform
US9402876B2 (en) 2013-11-27 2016-08-02 Industrial Technology Research Institute Method and pharmaceutical composition for hair growth
WO2018119142A1 (fr) 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
KR102372512B1 (ko) * 2017-11-20 2022-03-10 가톨릭대학교 산학협력단 폴리감마글루탐산 및 메토트렉세이트를 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물
CN116688094A (zh) * 2021-12-15 2023-09-05 苏州澳宗生物科技有限公司 p75细胞外结构域在类风湿性关节炎治疗和/或预防中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8608068D0 (en) 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
EP0288088B1 (fr) 1987-04-24 1994-03-09 Teijin Limited Détection du facteur nécrosant de tumeur; anticorps monoclonal et composition
GB8805792D0 (en) 1988-03-11 1988-04-13 Celltech Ltd Medicaments
US5260422A (en) 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
KR920702621A (ko) * 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
DE69027121T3 (de) 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US5298396A (en) 1989-11-15 1994-03-29 National Jewish Center For Immunology And Respiratory Medicine Method for identifying T cells disease involved in autoimmune disease
DE69028713T3 (de) 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
DE4006269A1 (de) 1990-02-28 1991-08-29 Max Planck Gesellschaft Antikoerper gegen den tumor-nekrosefaktor-rezeptor
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GB9023783D0 (en) 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
US5958413A (en) 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
AU8910891A (en) 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
DE4108204A1 (de) 1991-03-14 1992-09-17 Schering Ag Verfahren zur herstellung von alkoxymagnesiumhalogeniden
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP1097945B1 (fr) 1991-03-18 2007-07-04 New York University Anticorps monoclonaux et chimèriques dirigés spécifiquement contre le facteur humain de nécrose tumorale
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993007863A1 (fr) 1991-10-15 1993-04-29 Mullarkey Michael F Procedes et compositions servant a traiter des reactions allergiques
US5201329A (en) * 1992-01-21 1993-04-13 Claire Quackenbush Permanent wave rod having hinged end-cap
US5580873A (en) 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
WO1995009652A1 (fr) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Traitement des troubles auto-immuns et inflammatoires
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) 1992-10-08 2004-08-03 The Kennedy Institute Of Rheumatology TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
AU5152293A (en) 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
DE4320157A1 (de) 1993-06-18 1994-12-22 Bayer Ag Verwendung von 1,2,4-Dithiazolium-Salzen als Chemotherapeutica
ES2153384T3 (es) 1993-07-30 2001-03-01 Kennedy Inst Of Rheumatology Metodo para tratar la esclerosis multiple.
AU7965694A (en) 1993-10-15 1995-05-04 Curators Of The University Of Missouri, The Dna encoding the human p2u receptor and null cells expressing p2u receptors
US20020068057A1 (en) 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB2289218A (en) 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
US5525613A (en) * 1994-06-16 1996-06-11 Entropin, Inc. Covalently coupled benzoylecgonine ecgonine and ecgonidine
US5530157A (en) * 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
WO1996033204A1 (fr) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf)
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
AU2012202134B2 (en) 1996-08-01 2013-02-14 The Kennedy Trust For Rheumatology Research Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
DE19650115C1 (de) 1996-12-03 1998-07-02 Fraunhofer Ges Forschung Medikamenten-Dosiervorrichtung
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
PL4006269T3 (pl) 2021-11-15 2024-06-17 E-Parktower GmbH Urządzenie do przechowywania /parkowania pojazdów

Also Published As

Publication number Publication date
CA2791778A1 (fr) 1998-02-12
CA2261630C (fr) 2012-12-04
US20060099212A1 (en) 2006-05-11
PT1593393E (pt) 2012-02-09
US20130064816A1 (en) 2013-03-14
ES2378446T3 (es) 2012-04-12
DK1593393T3 (da) 2012-02-13
US20090175859A1 (en) 2009-07-09
AU3703597A (en) 1998-02-25
EP1593393B1 (fr) 2011-11-30
PT1941904E (pt) 2012-08-03
US8298537B2 (en) 2012-10-30
US20120141475A1 (en) 2012-06-07
EP1941904B1 (fr) 2012-05-16
EP1941904A2 (fr) 2008-07-09
HK1020011A1 (en) 2000-03-10
ATE535255T1 (de) 2011-12-15
EP0914157A1 (fr) 1999-05-12
US8383120B2 (en) 2013-02-26
US7846442B2 (en) 2010-12-07
EP1941904A3 (fr) 2009-09-09
ES2247635T3 (es) 2006-03-01
US20110123543A1 (en) 2011-05-26
CA2261630A1 (fr) 1998-02-12
US20020010180A1 (en) 2002-01-24
ATE305798T1 (de) 2005-10-15
EP1593393A3 (fr) 2007-12-12
DK1941904T3 (da) 2012-07-16
LU92098I2 (fr) 2013-01-16
ES2388244T3 (es) 2012-10-11
EP1593393A2 (fr) 2005-11-09
AU719015B2 (en) 2000-05-04
WO1998005357A1 (fr) 1998-02-12
US7838489B2 (en) 2010-11-23
US6270766B1 (en) 2001-08-07
US20020136723A1 (en) 2002-09-26
DE69734317D1 (de) 2006-02-16
US20120141474A1 (en) 2012-06-07
US20110014188A1 (en) 2011-01-20
LU92004I2 (fr) 2012-07-23
LU92099I2 (fr) 2013-01-16
DE69734317T2 (de) 2006-07-20
EP0914157B1 (fr) 2005-10-05
DK0914157T3 (da) 2006-01-30

Similar Documents

Publication Publication Date Title
LU92099I2 (fr) Golimumab et ses dérivés pharmaceutiquement acceptables (SIMPONI®)
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
FI920956A0 (fi) Doseringsform foer administrering av oral hypoglykemisk glipisid.
GB8817015D0 (en) Method of treatment
MX9700081A (es) Composiciones farmaceuticas de tacrina.
NO923859L (no) Medikament
EP0377520A3 (fr) Utilisation de la nicotine pour la fabrication d'un kit utilisé dans le traitement des maladies susceptibles de ce traitement
GB9727131D0 (en) Therapeutic agents
SE8500996D0 (sv) Method of treatment
ES2121103T3 (es) Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.
EP0338679A3 (fr) Utilisation du facteur necrosant des tumeurs dans le traitement du cancer de la vessie
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
EA200000448A1 (ru) Новые полиморфные формы ципамфиллина
EP0378146A3 (fr) Dérivés de polyamine comme agents antinéoplastiques
CA2392902A1 (fr) Bisindolylmaleimides substitues destines a inhiber la proliferation cellulaire
BE1002099A3 (fr) Nouvelles quinazolinones tetracycliques, leur preparation et leur utilisation comme medicaments.
HU913660D0 (en) The use of imidoazepine derivatives for treating of sleep impairments
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
WO2000033823A3 (fr) Procedes d'utilisation de temozolomide dans le traitement de cancers
AU580050B2 (en) Triazolopyrimidine derivatives
WO2002019964A3 (fr) Procedes et compositions pharmaceutiques utilisant la desmethylselegiline pour traiter des maladies ou des etats neoplasiques
MD1588F1 (en) Method of burn shock treatment
UA30654A (uk) Спосіб лікування посттравматичних дисфункцій висково- нижньощелепового суглоба
UA23882A (uk) Спосіб лікування виразкової хвороби дванадцятипало ї кишки
RU99122488A (ru) Способ лечения рака эндометрия